Sökning: WFRF:(von Arx Claudia) >
Early Identificatio...
Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest)
-
- Modlin, Irvin M. (författare)
- Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06520 USA.
-
- Kidd, Mark (författare)
- Wren Labs, Branford, CT USA.
-
- Öberg, Kjell, 1946- (författare)
- Uppsala universitet,Science for Life Laboratory, SciLifeLab,Endokrin tumörbiologi
-
visa fler...
-
- Falconi, Massimo (författare)
- Ist Sci San Raffaele, IRCCS, Milan, Italy.
-
- Filosso, Pier Luigi (författare)
- Univ Turin, Turin, Italy.
-
- Frilling, Andrea (författare)
- Imperial Coll London, London, England.
-
- Malczewska, Anna (författare)
- Med Univ Silesia, Katowice, Poland.
-
- Salem, Ronald (författare)
- Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06520 USA.
-
- Toumpanakis, Christos (författare)
- Royal Free Hosp, London, England.
-
- Laskaratos, Faidon-Marios (författare)
- Royal Free Hosp, London, England.
-
- Partelli, Stefano (författare)
- Ist Sci San Raffaele, IRCCS, Milan, Italy.
-
- Roffinella, Matteo (författare)
- Univ Turin, Turin, Italy.
-
- von Arx, Claudia (författare)
- Imperial Coll London, London, England.
-
- Kudla, Beata Kos (författare)
- Med Univ Silesia, Katowice, Poland.
-
- Bodei, Lisa (författare)
- Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
-
- Drozdov, Ignat A. (författare)
- Wren Labs, Branford, CT USA.
-
- Kitz, Alexandra (författare)
- Wren Labs, Branford, CT USA.
-
visa färre...
-
Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06520 USA Wren Labs, Branford, CT USA. (creator_code:org_t)
- 2021-05-18
- 2021
- Engelska.
-
Ingår i: Annals of Surgical Oncology. - : Springer. - 1068-9265 .- 1534-4681. ; 28:12, s. 7506-7517
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction Surgery is the only cure for neuroendocrine tumors (NETs), with R0 resection being critical for successful tumor removal. Early detection of residual disease is key for optimal management, but both imaging and current biomarkers are ineffective post-surgery. NETest, a multigene blood biomarker, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scores post-surgery would predict recurrence. Methods This was a multicenter evaluation of surgically treated primary NETs (n = 153). Blood sampling was performed at day 0 and postoperative day (POD) 30. Follow-up included computed tomography/magnetic resonance imaging (CT/MRI), and messenger RNA (mRNA) quantification was performed by polymerase chain reaction (PCR; NETest score: 0-100; normal <= 20). Statistical analyses were performed using the Mann-Whitney U-test, Chi-square test, Kaplan-Meier survival, and area under the receiver operating characteristic curve (AUROC), as appropriate. Data are presented as mean +/- standard deviation. Results The NET cohort (n = 153) included 57 patients with pancreatic cancer, 62 patients with small bowel cancer, 27 patients with lung cancer, 4 patients with duodenal cancer, and 3 patients with gastric cancer, while the surgical cohort comprised patients with R0 (n = 102) and R1 and R2 (n = 51) resection. The mean follow-up time was 14 months (range 3-68). The NETest was positive in 153/153 (100%) samples preoperatively (mean levels of 68 +/- 28). In the R0 cohort, POD30 levels decreased from 62 +/- 28 to 22 +/- 20 (p < 0.0001), but remained elevated in 30% (31/102) of patients: 28% lung, 29% pancreas, 27% small bowel, and 33% gastric. By 18 months, 25/31 (81%) patients with a POD30 NETest >20 had image-identifiable recurrence. An NETest score of >20 predicted recurrence with 100% sensitivity and correlated with residual disease (Chi-square 17.1, p < 0.0001). AUROC analysis identified an AUC of 0.97 (p < 0.0001) for recurrence-prediction. In the R1 (n = 29) and R2 (n = 22) cohorts, the score decreased (R1: 74 +/- 28 to 45 +/- 24, p = 0.0012; R2: 72 +/- 24 to 60 +/- 28, p = non-significant). At POD30, 100% of NETest scores were elevated despite surgery (p < 0.0001). Conclusion The preoperative NETest accurately identified all NETs (100%). All resections decreased NETest levels and a POD30 NETest score >20 predicted radiologically recurrent disease with 94% accuracy and 100% sensitivity. R0 resection appears to be ineffective in approximately 30% of patients. NET mRNA blood levels provide early objective genomic identification of residual disease and may facilitate management.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Modlin, Irvin M.
-
Kidd, Mark
-
Öberg, Kjell, 19 ...
-
Falconi, Massimo
-
Filosso, Pier Lu ...
-
Frilling, Andrea
-
visa fler...
-
Malczewska, Anna
-
Salem, Ronald
-
Toumpanakis, Chr ...
-
Laskaratos, Faid ...
-
Partelli, Stefan ...
-
Roffinella, Matt ...
-
von Arx, Claudia
-
Kudla, Beata Kos
-
Bodei, Lisa
-
Drozdov, Ignat A ...
-
Kitz, Alexandra
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Annals of Surgic ...
- Av lärosätet
-
Uppsala universitet